RKVTF
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more
RKVTF (RKVTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.548x
Based on the latest financial reports, RKVTF (RKVTF) has a cash flow conversion efficiency ratio of -0.548x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.04 Million) by net assets ($1.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RKVTF - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how RKVTF's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RKVTF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RKVTF ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tri Banyan Tirta Tbk
JK:ALTO
|
0.004x |
|
Wang-Zheng Bhd
KLSE:7203
|
0.013x |
|
HARTFORD FIN SERV
BE:HFF
|
0.099x |
|
VHAI
BATS:VHAI
|
0.035x |
|
Integritas Viager SA
PA:MLVIE
|
N/A |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
-0.078x |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
-0.003x |
|
Hong Yuan Holding Group
PINK:HGYN
|
0.583x |
Annual Cash Flow Conversion Efficiency for RKVTF (2021–2024)
The table below shows the annual cash flow conversion efficiency of RKVTF from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $4.30 Million | $-3.86 Million | -0.897x | -76.29% |
| 2023-09-30 | $3.66 Million | $-1.86 Million | -0.509x | -59.59% |
| 2022-09-30 | $6.01 Million | $-1.92 Million | -0.319x | -17.99% |
| 2021-09-30 | $8.54 Million | $-2.31 Million | -0.270x | -- |